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•	 Caspase-9 is an important enzyme for apoptosis and its activity is pivotal in cell death.
•	 A computational design of small molecular inhibitors for caspase-9 performed by structure-based 
pharmacophore model.  
•	 9 compounds from both National Cancer Institute (NCI) and ZINC databases were discovered as potent 
inhibitors.
* Corresponding Author: 
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ABSTRACT
Caspases are enzymes which are the main pathways for apoptosis. Any irregulation in their 
functions causes increase or decrease in cell death, which result in autoimmune disease or 
cancer, respectively. In this study, structure-based pharmacophore drug discovery method 
as a virtual screening was used to discover selective inhibitors for caspase-9. This enzyme 
is an initiator caspase that is the main pathway in Alzheimer’s disease. A pharmacophore 
model was developed by investigating essential interactions among the reported potent 
inhibitors employing a docking analysis methodology. Applying pharmacophore virtual 
screening, nine compounds from both National Cancer Institute (NCI), and ZINC 
databases	were	filtered	as	potent	inhibitors	of	caspase-9.	The	efficiency	of	the	discovered	
compounds was further investigated by docking studies.
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Introduction 
Apoptosis is a programmed cell death which is a crucial 
process in development, maintenance of cell homeostasis, 
and regulation of immune system. When the apoptosis is 
either	 excessive	 or	 insufficient,	 it	 could	 result	 in	many	
disease including cancer, autoimmune disease, viral 
infection, and neurological disorders (Rudel, 1999; 
Talanian et al., 2000). 
In mammalian, apoptosis is activated throughout 
three main pathways by caspase enzymes whose names 
are given from their ability in the cleavage of substrates 
after an Asp residue (Shi, 2002): extrinsic (death 
receptor pathway), intrinsic (apoptosome pathway), and 
cytotoxic lymphocyte-initiated granzyme B pathway 
(Cullen and Martin, 2009). In extrinsic and intrinsic 
pathways, apoptosis is driven by caspases from initiators 
(caspase-8, 9) to effectors (caspase-3, 7). Thus, activation 
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and inhibition of initiator caspases is a central regulatory step 
in cellular physiology (Shi, 2005) and has made caspases 
considerable targets to design cytoprotective drugs. Also, 
the inhibition of excessive apoptosis is considered as the 
main ways to treat or reduce signs of disease (Yaoita et 
al., 1998; Braun et al., 1999; Cursio et al., 1999; Schulz 
et al., 1999; Lee et al., 2000; Mocanu et al., 2000). 
Oxidative damage, by aging and disease, leads to 
mitochondria dysfunction, releasing cytochrome C 
and then it activates Caspase-9 continued by effectors 
caspases (Rohn et al., 2002). There are some evidences 
confirming	 that	 the	 cleavage	 of	Asp421	 by	 caspases	 is	
more rapid in tau cleavage, so capases activation could 
hyperphosphorilize tau proteins and have effective rules 
in the cleavage of amyloid precursor protein (APP), 
and tau protein (Rohn and Head, 2009; Rohn, 2010). 
Enhancement	 in	 tau	 proteins	 increases	 neurofibrillary	
tangles (NFTs) (Rohn et al., 2002).
Extracellular	 plaques	 of	 amyloid-β	 and	 intercellular	
neurofibrillary	tangles	(NFTs)	are	defined	in	Alzheimer’s	
disease as a progressive disorder (Chong et al., 2005). 
Since caspase-cascade is a very effective pathway for 
apoptosis (Denault and Salvesen, 2002; Shiozaki et al., 
2003), in this study caspase-9 inhibition was investigated. 
Caspase-9 belongs to caspases initiator class, which is 
activated by death stimulus in upstream. So, its inhibition 
causes stopping cell  death during the caspase cascade 
(Cohen, 1997; Denault and Salvesen, 2002; Philchenkov, 
2004).	
Caspases have a special recognition sequence including 
at least four N-terminal amino acids in their active site 
(Rudel, 1999; Grutter, 2000). Active site in caspase-9 
is recognized by a four amino acid sequence (LEHD) 
involving an aspartic acid residue in the P1 position and 
a small hydrophobic residue in the P2 position, in CARD 
domain from caspase-3, 7, and then by limited proteolysis 
change of them to active forms (Rudel, 1999; Grutter, 
2000; Renatus et al., 2001; Yang et al., 2003; Yoshimori 
et al., 2007) 
Structure-based pharmacophore model generating 
from the optimal interactions of already experimentally 
reported inhibitors with the target macromolecular is 
defined	as	a	very	helpful	method	for	screening	a	 ligand	
database and more effective inhibitor models. Then, 
the obtained information enable medicinal chemists to 
develop	molecules	with	higher	binding	affinities	 for	 the	
target	macromolecule	and	can	be	used	to	generate	specific	
biological responses (Yoshimori et al., 2007).  
In this study, a computational design was performed 
for selection of small molecular inhibitors against 
Caspase-9 by developing and modifying a pharmacophore 
model based on teripeptidyl inhibitor (PHQ-GLU-
VAL-ASP), which is recrystallized in the Protein 





Protein	Data	Bank	 (pdb	 code,	 1	 jxq,	 2.80	Ǻ)	 (Shiozaki	
et	 al.,	2003;	Philchenkov,	2004).	The	pdb	structure	was	
refined	due	to	a	large	missing	part	in	the	crystallographic	
structure. This missing sequence contained 35 amino acids 
(ASTSPEDESPGSNPEPDATPFQEGLRTFDELDAIS). 
Homology	modeling	strategy	was	applied	to	fix	the	large	
gap in the structure. Since there was no crystallographic 
structure with an acceptable similarity to that of 
caspase-9 by complete amino acid sequencing, caspase-9 
structure was found by blasting the enzyme sequence 
employing the online program BLAST from NCBI. 
Then, it was decided to solely perform homology model 
with the missing part. The target sequence was aligned 
to those with similar sequence to identify appropriate 
templates for the subsequent homology modeling 
procedure. MODELER 9.10 (Sali and Blundell, 1993) 
employed	four	structures	with	PDB	IDs	of	4DGE,	4DGA,	
2PBj, and 1Z9H as the appropriate templates to build the 
missing part structure of caspase-9. While the obtained 
structure	 mainly	 contains	 loops	 and	 turns,	 an	 α-helix	
(DELDAIS)	 and	 a	 β-sheet	 (ASTS)	were	 also	 observed.	
This structure was linked to that of the crystallographic 
one with the aid of  Hyperchem 8.0 and then, GROMACS 
MD	 package	 4.5.5	 and	 GROWMOS96	 53ab	 as	
classical molecular dynamic simulations (MDs), using 
for minimizing and optimizing of energy and also an 
appropriate	structure	was	achieved	after	40	nanoseconds	
of MDs (Fig. 1). 
The Ramachandran plot of the enzyme average 
structure during the equilibration state was plotted 
(Fig.	2).	Obviously,	only	4	amino	acids	of	 the	modeled	
sequence are in the forbidden region and two out of four 
are Gly that can be present in both regions. Therefore, the 
obtained overall enzyme was employed for the rest of the 
study. 
Docking methodology
Autodock	 tools	 1.5.4	 were	 used	 for	 preparing	 input	
files.	 The	 grid	 maps	 were	 calculated	 and	 the	 docking	
procedure	was	performed	by	Auto	grid	4.2	and	Auto	dock	
4.2,	 respectively.	 Ligands	 docked	 on	 Caspase-9	 were	
those from binding database, reported until August 2012 
(Liu et al., 2007).
The	grid	box	of	126,	126,	126	Ǻ	(x,	y	and	z)	as	 the	
large	grid	box	and	66,	66,	68	Ǻ	(x,	y	and	z)	as	the	small	
grid box were assigned on caspase-9 binding pocket with 
the	spacing	of	0.375	Ǻ.	Other	docking	study	parameters	
were as follow: number of Lamarckian job=100; initial 
population =100; maximum number of energy evaluation 
=25×105; maximum generations =27000; mutation rate 
37
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of 0.02.; a crossover rate of 0.80. 
Pharmacophore model generation and virtual screening
Structure based pharmacophore model approach was 
used for considering the ligands modes of interactions in 
the protein binding pocket. LigandScout v.301 software 
was	 employed	 for	 development	 and	 refinement	 of	 all	
pharmacophore models (Wolber and Langer, 2005). 
The	 obtained	 models	 were	 then	 used	 as	 filters	 during	
the virtual screening by Ligandscout v.301 to extract 
ligands with desired pharmacophore features from NCI 
and ZINC compound databases (each compound in 
its 25 conformers). 
Classical molecular dynamic simulations
GROMACS	 MD	 package	 4.5.5	 and	 GROWMOS96	
force	field	are	reinforced	for	classical	molecular	dynamic	
simulations (Pronk et al., 2013). PRODRG server was 
applied	to	obtain	the	ligand’s	topology	files	(Schuttelkopf	
and	van	Aalten,	2004).	The	initial	structure	that	contained	
caspase-9 in complex with the target ligand in their best 
mode of interaction according to the calculated binding 
energy and orientations in the binding pocket was derived 
from the former docking studies. The desired complex 
was immerged in a dodecahedron-shaped box (X, Y and 
Z) with minimum distance of 1nm from each edge of 
the box, while, periodic boundary conditions were also 
Table 1. Details of the best ligands elicited from pharmacophore search based on docking studies. (Abbreviations; LS: Ligand Scout, hyd: 
hydrophobic,	 acc:	 acceptor,	 aro:	 aromatic,	 don:	 donor,	 pos:	 position).	 Structure	 of	 ligands	were	 depicted	 in	 figure	 4.
Ligand  BindingEnergy
 LS pharmacophore
feature H-bond contacts MW xlogP
a
2a -9.29 3 hyd, 2 acc, 1 aro Arg 335, Gly 238, Cys 287 409 	6.26
2b -6.89 3 hyd, 3 acc   Arg 355, Arg 180, Cys 287, Ser 353, Gly 238 397.441 4.05
2c -7.12 4	hyd,	2	acc,	1	aro Thr 181 454.448 4.14
2d -7.19 2 hyd, 1 acc Arg355, Arg 180 484.474 4.20
2e -7.08 3 hyd, 1 acc Tyr 251 460.477 4.51
2f -6.88 4	hyd,	2	acc,	1	aro Arg 180, Tyr 251 479.458 3.90
2g -6.30 5 hyd, 1 acc Arg 355 438.471 3.43
2h -6.63 3 hyd, 1 acc, 1 don Arg 355, Glu 290 483.49 5.38
2i -6.85 1 hyd, 1 acc, 1 pos Tyr 251 466.483 4.71
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assigned in all directions. Some Na+ counter ions were 
substituted by water molecules randomly to neutralize 
the system net charge. Steepest descent algorithm was 
employed to minimize energy of system. The system went 
through NVT ensemble MD simulations for 20ps right 
after convergence, followed by simulations under NPT 
ensemble at 300 K.  Berendsen barostat and thermostat 
were used to keep the pressure and temperature constant 
at 1 bar and 300 K. The partial mesh Ewald method was 
used to calculate long-rage electrostatic interactions. For 
restraining, the bond lengths LINCS was employed with 
an integration step of 1 fs. The MD simulations were 
extended NPT for 10 nanoseconds at constant pressure 
and temperature conditions. 
Data analysis and presentation software
LigandScout	 v3.01,	 Autodock	 tools	 1.5.4,	 Discovery	
studio v3.5 and PyMOL software were used to analyze 
and visualize all ligand–protein interactions. PyMOL was 
also employed to better illustrate ligand-proteins modes 
of interactions for MD simulations studies.
Results and Discussion
Docking studies and model creation 
For validation of docking method in the best docked 
conformation, RMSD (root mean square deviation) 
extracted from experimental, should be <2.0 Å, then, the 
used scoring function is acceptable (Wang et al., 2003). In 
our validation, RMSD value was excellent for the native 
ligand,	which	was	0.623	Å.
A Structure-based pharmacophore model was 
generated according to a three amino acid peptide in the 
crystallised structure of the caspase-9 protein. The model 
was	 further	 modified	 according	 to	 the	 structure	 of	 the	
active pocket. In these structure-based generated models 
(models 2-pharmacophore) virtual screening resulted in 
19 compounds to be considered as caspase-9 inhibitors. To 
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was done on 19 compounds in model 2-pharmacophore in 
which	finally	9	compounds	were	achieved.	The	extracted	
compounds	affinities	were	ranked	by	employing	docking	
methodology. Rigid docking studies were carried out 
using	 Autodock	 4.2,	 and	 the	 results	 are	 presented	 in	
Table1. 
Pharmacophore virtual screening is taken out on some 
compounds according to their similarity to the models 
and further continued by docking methodology to extract 
those	with	 higher	 affinity	 for	 the	 active	 site.	According	
to the docking studies results, models 2-pharmacophore 
resulted	 in	 9	 compounds	 with	 considerable	 affinities	
for the active site. The proper compounds were chosen 
based on their docking binding energy value, drug like 
parameters, and also their orientation in the pocket. 
Among obtained compounds, 2a was selected as the best 
because of the best binding energy, including critical 
interaction by amino acids in active site of the receptor’s 
pocket. Molecular dynamics was carried out on 2a as the 
best parameters to interact with caspase-9.
Protein crystallography structure includes two-chain 
caspase	9	which	missed	first	138	 residue	by	proteolytic	
removal of the CARD. The crystal contains teripeptidyl 
inhibitor in active site (Renatus et al., 2001). It should also 
be mentioned that Arg 355, Arg 180, His 237, and Cys 287 
are the key amino acids of the active pocket of enzyme 
caspase-9 as it was already reported in the literature 
(Renatus et al., 2001; Chao et al., 2005; Yoshimori et al., 
2007). Further, hydrophobic and H-bonding interactions 
are the main contacts between the ligands and the active 
site. 
The crystallographic structure and the peptide 
sequence in the active site were studied thoroughly 
and were used for pharmacophore model generation. 
Model1-pharmacophore was generated focusing on the 
interactions of a teripeptidyl sequence PHQ-GLU-VAL-
ASP trapped in the active pocket (Fig. 3.a). The model 
1 included H-bond acceptors (red arrows) which showed 
that	there	were	4	H-bond	acceptors	via	His237,	Arg180,	
and  Arg355  (Renatus et al., 2001; Chao et al., 2005; 
Yoshimori et al., 2007). Moreover, a hydrophobic area 
was	created	in	Ile382,	Trp354,	and	Val338	area.	The	two	
negative ionizable interactions occurred as a result of the 
carboxylate functional groups of the peptide amino acids 
(Glu and Asp). 
By virtual screening of the database of the 
pharmacophore model1-pharmacophore, no coincident 
structure with this model was obtained. Consequently, 
to broaden the applicability of the model, the number 
of pharmacophores was reduced by omitting the two 
negative ionizable pharmacophores. To more specify 
Model 2-pharmacophore, the techniques  of structure-
based pharmacophore modeling was used and a hydrogen 
bond acceptor pharmacophore with original position 
(Orig.	Pos.)	23.80,	43.67,	 and	 -8.98,	 tolerance	1.5,	 and	
weight 1, was created through NH functional group of 
Cys287 (model 2-pharmacophore, Fig. 3.c). 
Model 2-pharmacophore screening resulted in 19 
compounds, after that, docking studies by a blind dock 
on	active	pocket,	9	compounds	(2a-i,	Fig.	4)	were	found	
to	have	better	 affinities	 and	orientation	 to	 interact	with	
the critical residues of the caspase-9 active site. The 
exact type of these compounds interactions and binding 
energies were further investigated. Docking procedure 
was repeated assigning small grid box on the active site, 
and	the	final	results	are	reported	in	Table	1.	
Figure 3. Pharmacophore model (model 1)generated from 1JXQ/
tripeptidyl sequence PHQ-GLU-VAL-ASP a. red arrows; HBA, 
yellow spheres; hydrophobic sites, gray spheres; excluded volumes, 
and red stars; negative ionizable interactions. b. the pharmacophore 
model interactions with the active pocket residues. c.	The	modified	
pharmacophore model (model 2-pharmacophore), (red arrows; HBA, 
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Molecular dynamic simulations
According to the calculated docking binding energy 
value and its modes of interactions, an appropriate 
conformation of the most potent ligand in complex with 
caspase-9 was obtained to be compound 2a. 
The complex of compound 2a with caspase-9 was 
assigned to classical molecular dynamic simulations to 
further evaluate the obtained binding pose stability and 
the ligands consistency in the active pockets in a dynamic 
environment while the solvent effects were also included. 
The backbone root mean square deviations (RMSD) of 
the protein backbone as well as the ligand itself were 
plotted with respect to their initial structure (the energy 















Figure 5. RMSD plots of a. Caspase-9 backbone in complex with ligand 2a (blue), and b. Ligand 2a backbone in complex with caspase-9, during 
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minimized structure) and as a function of the simulation 
time to ensure the system reached the equilibration 
state.	As	it	 is	shown	in	Fig.	5,	no	significant	deviations	
were observed for both the protein backbone and the 
ligand	which	 indicated	 the	efficiency	of	 the	established	
interactions between them. In point of fact, while notable 
deviations were observed in the ligand conformation for 
the	 establishment	 of	 efficient	 interactions	 in	 caspase-9	
binding	 pocket	 in	 the	 first	 3	 nanoseconds	 of	 the	
simulation	 time	which	 then	 almost	 became	fixed	 in	 its	
position,	the	protein	did	not	need	to	go	under	significant	
conformational changes for the formation of a conducive 
binding. 
Further, to better observe the enzyme residues 
behavior throughout MD simulations time, root mean 
square	 fluctuations	 (RMSF)	 of	 the	 amino	 acids	 were	
calculated	 and	 graphed.	According	 to	 Fig.	 4,	 residues	
Arg180,	 His237,	 Gly238,	 Tyr251,	 Ala286,	 Cys287,	
and	 Trp354	 showed	 the	 least	 fluctuations	 because	 of	
their presence in the pliable parts of the protein, loop, 
and turn structures. This rigidity can be attributed to the 
involvement of the mentioned residues in interaction 
with	 the	 ligand.	Also	a	very	 significant	fluctuation	was	
observed	for	residue	Pro357	(Fig.	6)	confirming	that	this	
residue has to change its orientations in order to establish 
better	electrostatic	interactions	with	the	diphenyl	sulfide	
fragment of the compound. 
According to the results obtained via the performed 
molecular dynamic simulations, the compound standed 
firm	in	the	binding	pose	was	obtained	from	the	docking	
studies and was stabilized in the pocket by the interactions 
discussed. 
The studied ligand average position during 10 
nanoseconds of MD simulations is shown in Fig. 
7. Several hydrogen bonds were formed between 
compound	2a	and	Arg180,	Cys287,	Arg355	and	Trp354	
(the red dashes). Also electrostatic interactions between 
diphenyl	sulfide	benzene	rings,	and	residues	Trp354	and	
Pro357	were	quite	inevitable.	Further,	the	fluorphosphate	
fragment enabled several salt bridge formations as well. 
The stability of the hydrogen bonds formed between 
the ligand and active pocket residues was computed as 
well. Based on Fig. 8, as the simulations progress, the 
hydrogen bonds number increases as well, showing that 
the dynamic nature of the simulations method gives the 
chance	 to	 both	 protein	 and	 the	 ligand	 to	 fit	 into	 their	
best conformations where they can conduct productive 
interactions. Also, this phenomenon provided more 
evidences the ligand stability in caspase-9 binding pocket.
The catalytic site structures of caspase-9 enzyme 
after energy minimization and 10 nanoseconds of 
MD simulations were superimposed to get a better 
insight of the impact of the dynamic environment of 
the modes of interactions. As it is presented in Fig. 9, 
the	 residues	 (Trp354,	 Pro357	 and	Arg355)	 orientations	
that	 are	 interacting	with	 diphenyl	 sulfide	 fragment	 has	
changed dramatically as well as the conformation of the 
target	fragment	itself,	but	 the	mode	of	 interactions	(π-π	
electrostatic interactions) did not show any changes. In 
contrast,	 quinoline	 as	well	 as	fluorphosphate	 fragments	
seem	to	have	stayed	almost	fixed	 in	 their	positions	due	
to the establishment of hydrogen bonds, salt bridges, and 
also protonated salt bridges that kept both the ligand, and 
the	involved	residues	firm,	as	well	as	the	rigid	nature	of	
this part of the ligands structure. 
Conclusion
This study indicates that the combined structure-based 
pharmacophore drug discovery method, pharmacophore 
















S. Ansari et al. / TPPS 2017 2 (1) 35-43
42
virtual screening, and docking analysis methodology 
have	 been	 effective	 approaches	 for	 the	 identification	
and characterization of the potent inhibitors of 
caspase-9.
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